• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

手术病理材料中miRNA表达谱与乳腺癌患者Ki-67、HER2、ER和PR的相关性

Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.

作者信息

Sakurai Minako, Masuda Mariko, Miki Yasuhiro, Hirakawa Hisashi, Suzuki Takashi, Sasano Hironobu

机构信息

1 Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi - Japan.

出版信息

Int J Biol Markers. 2015 May 26;30(2):e190-9. doi: 10.5301/jbm.5000141.

DOI:10.5301/jbm.5000141
PMID:25907662
Abstract

BACKGROUND

New molecular markers related to prognosis and/or clinical outcome have been extensively studied in breast cancer. In particular, microRNA (miRNA) has attracted the interest of both basic and clinical investigators as one of the promising molecular markers of breast cancer patients. MiRNAs are a class of short noncoding RNAs that regulate mRNAs at posttranscriptional level and are deregulated in various human malignancies. Previous studies have reported that miRNAs were stably conserved in 10% formalin-fixed paraffin-embedded tissues without significant degradation, in contrast to more fragile RNA.

METHODS

Therefore, in this study, we examined 21 surgical breast cancer specimens using the Human Cancer microRNA PCR Array system (QIAGEN) to explore potential molecular targets of miRNAs.

RESULTS

Profiling of miRNA expression in archival materials demonstrated that a group of deregulated miRNAs was associated with clinicopathological parameters of the patients, such as Ki-67, HER2, ER and PR. For instance, an abundant expression of multiple let-7 miRNA family, also known as tumor suppressor, was detected in low Ki-67 and HER2 groups. Elevated expression of 8 miRNAs overlapped between Ki-67+/HER2+/ER+/PR+ groups, including several known oncogenic miRNAs such as miR-148b, miR-15b, miR-200c, miR-150, miR-191, miR-96, miR-25 and miR-21.

CONCLUSIONS

These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.

摘要

背景

与乳腺癌预后和/或临床结局相关的新分子标志物已得到广泛研究。尤其是,微小RNA(miRNA)作为乳腺癌患者有前景的分子标志物之一,吸引了基础和临床研究人员的关注。miRNA是一类短的非编码RNA,在转录后水平调节mRNA,并且在各种人类恶性肿瘤中表达失调。先前的研究报道,与更易降解的RNA相比,miRNA在10%中性福尔马林固定石蜡包埋组织中稳定保守,无明显降解。

方法

因此,在本研究中,我们使用人类癌症miRNA PCR阵列系统(QIAGEN)检测了21例手术切除的乳腺癌标本,以探索miRNA的潜在分子靶点。

结果

存档材料中miRNA表达谱分析表明,一组表达失调的miRNA与患者的临床病理参数相关,如Ki-67、HER2、雌激素受体(ER)和孕激素受体(PR)。例如,在低Ki-67和HER2组中检测到多个也被称为肿瘤抑制因子的let-7 miRNA家族的丰富表达。8种miRNA的表达升高在Ki-67+/HER2+/ER+/PR+组中重叠,包括几种已知的致癌miRNA,如miR-148b、miR-15b、miR-200c、miR-150、miR-191、miR-96、miR-25和miR-21。

结论

这些结果均表明,当将乳腺癌手术病理标本中的miRNA作为生物标志物进行分析时,应通过miRNA谱分析将它们作为一个簇进行检测,而不是依赖于单个miRNA的分析。

相似文献

1
Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.手术病理材料中miRNA表达谱与乳腺癌患者Ki-67、HER2、ER和PR的相关性
Int J Biol Markers. 2015 May 26;30(2):e190-9. doi: 10.5301/jbm.5000141.
2
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.miRNA 特征可预测乳腺癌中雌激素受体、孕激素受体和 HER2/neu 受体状态。
Breast Cancer Res. 2009;11(3):R27. doi: 10.1186/bcr2257. Epub 2009 May 11.
3
Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.根据肿瘤类型分析乳腺癌中 miR-17-92 簇和 miR-17 家族的差异表达;来自挪威妇女与癌症(NOWAC)研究的结果。
J Transl Med. 2019 Oct 3;17(1):334. doi: 10.1186/s12967-019-2086-x.
4
MicroRNA regulation of progesterone receptor in breast cancer.微小RNA对乳腺癌中孕激素受体的调控
Oncotarget. 2017 Apr 18;8(16):25963-25976. doi: 10.18632/oncotarget.15657.
5
Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.腔面A型乳腺癌肿瘤学miRNA生物标志物的鉴定与验证
PLoS One. 2014 Jan 31;9(1):e87032. doi: 10.1371/journal.pone.0087032. eCollection 2014.
6
Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.雌激素受体和孕激素受体调节的 microRNAs 在乳腺癌中的表达。
Genes (Basel). 2021 Apr 16;12(4):582. doi: 10.3390/genes12040582.
7
Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.let-7a、miR-17、miR-27b、miR-125a、miR-125b和miR-206的相对水平作为评估乳腺癌分级、受体状态和分子类型的潜在分子标志物。
Mol Med Rep. 2015 Sep;12(3):4692-4702. doi: 10.3892/mmr.2015.4002. Epub 2015 Jun 26.
8
Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.鉴定乳腺癌中的 miRNA 特征以预测新辅助化疗反应。
Pathol Oncol Res. 2021 Apr 30;27:1609753. doi: 10.3389/pore.2021.1609753. eCollection 2021.
9
miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.微小RNA作为黎巴嫩人群及年轻女性乳腺癌潜在生物标志物的初步研究
PLoS One. 2014 Sep 18;9(9):e107566. doi: 10.1371/journal.pone.0107566. eCollection 2014.
10
Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.一种与乳腺干细胞相关的微小RNA特征在激素受体阳性、人表皮生长因子受体2阴性乳腺癌中的预后价值
EBioMedicine. 2016 Sep;11:199-209. doi: 10.1016/j.ebiom.2016.08.016. Epub 2016 Aug 17.

引用本文的文献

1
Evaluation of the Effect of Radiotherapy on CCL5/miR-214 -3p/MALAT1 Genes Expression in Blood Samples of Breast Cancer Patients.放疗对乳腺癌患者血液样本中CCL5/miR-214 -3p/MALAT1基因表达的影响评估
Int J Mol Cell Med. 2022;11(3):244-259. doi: 10.22088/IJMCM.BUMS.11.3.244.
2
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.Ki-67与乳腺癌的演变:过去的观察、当前的方向及未来的考量
Cancers (Basel). 2023 Jan 28;15(3):808. doi: 10.3390/cancers15030808.
3
miR-205-5p Downregulation and Upregulation Characterize the Disseminated Tumor Cells in Patients with Invasive Ductal Breast Cancer.
miR-205-5p 的下调和上调特征在浸润性导管乳腺癌患者的播散肿瘤细胞中。
Int J Mol Sci. 2021 Dec 22;23(1):103. doi: 10.3390/ijms23010103.
4
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer.Ki-67作为浸润性乳腺癌的预后生物标志物
Cancers (Basel). 2021 Sep 3;13(17):4455. doi: 10.3390/cancers13174455.
5
A myriad of roles of miR-25 in health and disease.miR-25在健康与疾病中的众多作用。
Oncotarget. 2018 Apr 20;9(30):21580-21612. doi: 10.18632/oncotarget.24662.
6
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.抗GD2-ch14.18/CHO包被的纳米颗粒介导芳香化酶抑制剂来曲唑对胶质母细胞瘤(GBM)的特异性递送,降低患者来源的GBM肿瘤细胞的增殖、迁移和化疗耐药性。
Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.
7
Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling.利用全基因组分析发现和验证与乳腺癌风险相关的微小RNA
Oncotarget. 2016 Dec 27;7(52):86457-86468. doi: 10.18632/oncotarget.13241.
8
Involvement of microRNAs in HER2 signaling and trastuzumab treatment.微小RNA在HER2信号传导及曲妥珠单抗治疗中的作用
Tumour Biol. 2016 Dec;37:15437–15446. doi: 10.1007/s13277-016-5405-3. Epub 2016 Oct 12.
9
miR-3646 promotes cell proliferation, migration, and invasion via regulating G2/M transition in human breast cancer cells.微小RNA-3646通过调控人乳腺癌细胞中的G2/M期转换来促进细胞增殖、迁移和侵袭。
Am J Transl Res. 2016 Apr 15;8(4):1659-77. eCollection 2016.
10
Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.miR-214和miR-218在乳腺癌中的肿瘤抑制作用。
Oncol Rep. 2016 Jun;35(6):3178-84. doi: 10.3892/or.2016.4749. Epub 2016 Apr 15.